Significant progress in the treatment of acute lymphoblastic leukemia (ALL) in children has resulted from the development of effective chemoand supportive care therapy protocols. The vector of further research is aimed at reducing toxicity and long-term side effects. The study of pharmacogenetic aspects of toxicity of the main drugs used in the treatment of ALL – methotrexate and 6-mercaptopurine – allowed to identify oligonucleotide polymorphisms that correlate with the concentration of the drug in blood, toxic effects and the risk of relapse of ALL. The clinical administration of pharmacogenetic methods remains a challenging task, requiring additional research, which will make it possible to individualize the ALL therapy on the basis of the results of molecular profiling.

Цель. Повышение эффективности и снижение токсичности терапии ОЛЛ у детей на основе фармакогенетического подхода при лечении метотрексатом.